"compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process"

LAP291AUndetermined Publication Date: 2025-11-14JOINT CO PHARMASYNTEZ
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP291
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2011-12-26
Filing Date
2012-05-17
Publication Date
2025-11-14

AI Technical Summary

Technical Problem

Current methods for preventing adhesion formation after surgical interventions are inadequate due to limitations such as ischemic areas being inaccessible to pharmacological agents, rapid absorption of intraperitoneal agents, and the need for specific action without interfering with normal wound healing, leading to ineffective and costly solutions with significant side effects.

Method used

Development of p38 MAP kinase blockers, specifically compounds like SB203580 and others of types (I)-(VII), which are administered to suppress excessive proliferative responses in serous membranes, preventing adhesion formation by blocking p38 MAP kinase activity and used in pharmaceutical compositions for direct application during surgical interventions.

Benefits of technology

The p38 MAP kinase blockers effectively prevent adhesion formation by suppressing pathological responses in serous membranes, reducing the risk of adhesions without interfering with normal healing processes, and can be administered once during surgery, simplifying the prevention method and reducing postoperative complications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The invention relates to the field of pharmacy, clinical and experimental medicine and veterinary mcdicine, and in particular to novel inhibitory compounds of a p38 MAP kinase with a structure of the type (I)-(VIl) which can be used for the treatment or prophylaxis of adhesion. The invention discloses pharmaceutical compositions contain ing an effective amount of the substance SB203580 or one of the compounds of the type (I)-(VII) or a combination thereof and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is: a method for the prophylaxis and / or treatment of a disease or a condition in which there is the possibility of the formation and / or growth of adhesions which makes it possible to dispense with the additional administration of a preparation in the post-operative period
Need to check novelty before this filing date? Find Prior Art

Description

[0001] COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR PREVENTION AND

[0002] TREATMENT OF ADHESION PROCESS

[0003] AREA OF TECHNOLOGY

[0004] The present invention relates to the fields of pharmacy, clinical or experimental medicine, or veterinary science, in particular to novel compounds for the treatment or prevention of adhesion formation, pharmaceutical compositions comprising these compounds, and a method for the prevention and / or treatment of adhesions. The compounds disclosed in the present invention exhibit p38 MAP kinase inhibition properties.

[0005] PRIOR ART

[0006] Adhesions are a pressing issue in clinical medicine. Because adhesions often impede normal tissue movement, including organ movement, they are considered a serious postoperative complication. The incidence of intra-abdominal adhesions ranges from 67% to 93% after general abdominal surgery and reaches nearly 97% after open gynecological procedures.

[0007] According to estimates, 117 people per 100,000 population are hospitalized in the United States due to adhesive disease, and the total costs for their hospitalization and treatment amount to 1.3 billion US dollars annually [Abdominal adhesiolysis: inpatient care and expenditures in the United States in 1994 / NF Ray, WG Denton, M. Thamer et alJ / J. Am. Coll. Surg.- 1998.- Vol. 186.- P. 1-9].

[0008] The main approaches to the prevention of adhesions include appropriate surgical technique with limitation of trauma to intra-abdominal structures and the use of auxiliary agents (adjuvants) that reduce adhesion formation [Risberg V. O. Adhesions: Preventive strategies / V. O. Risberg / / Eur. J. Surg. Suppl.- 1997.- Vol. 577.- P. 32-39].

[0009] However, the use of drugs for the prevention of adhesion formation is limited by a number of factors:

[0010] 1) ischemic areas are prone to the formation of adhesions, but they are cut off from the blood flow and, therefore, from the effects of pharmacological agents administered by conventional routes (per os, intravenously, intramuscularly, etc.);

[0011] 2) the extremely rapid absorption mechanism characteristic of the peritoneal membrane limits the half-life and effectiveness of many agents administered intraperitoneally;

[0012] 3) any anti-adhesive drug should act specifically against the process of adhesion formation, but not against normal wound healing, which is necessary for adequate surgical treatment.

[0013] Intraperitoneal administration of thrombokinase, fibrinolysin, streptokinase, urokinase, hyaluronidase, chymotrypsin, trypsin, papain and pepsin allows for a direct effect on fibrin masses by stimulating the activity of plasminogen activator, however, these drugs have not found wide clinical application [Alpay Z. Postoperative adhesions: from formation to prevention / Z. Alpay, GM Saed, MP Diamond / / Semin. Reprod. Med.- 2008.- Vol. 26, N 4.- P. 313-321].

[0014] The use of non-steroidal anti-inflammatory drugs, glucocorticoids and antihistamines, progesterone / estrogenic agents, anticoagulants, fibrinolytic drugs, and antibiotics is not effective enough and is hampered by inadequate safety and numerous side effects [Pathogenesis, consequences, and control of peritoneal adhesions in gynecologic surgery / Practice committee of the American society for reproductive medicine, The society of reproductive surgeons / / Fertil. Steril.- 2008.- Vol. 90, Suppl. 5.- S. 144-149].

[0015] A pathogenetically justified direction in the prevention of adhesion formation is considered to be the use of methods and means that prevent the convergence and gluing of injured surfaces of the peritoneum [Davey A.K. Surgical adhesions: A timely update, a great challenge for the future / AK Davey, PJ Maher / / J. of Minimally Invasive Gynecology.- 2007.- Vol. 14.- P. 15-22].

[0016] An ideal barrier, while being highly safe and effective, should not cause inflammation or immune reactions, should be maintained throughout the critical phase of remesothelialization, be held in place without sutures or staples, remain active in the presence of blood, and be completely absorbable. Furthermore, it should not disrupt healing, provoke infection or oncological processes, or cause adhesions [Yeo Y. Polymers in the prevention of peritoneal adhesions / Y. Yeo, DS Kohane / / European. J. of Pharmaceutics and Biopharmaceutics.- 2008.- Vol. 68.- P. 57-66].

[0017] As barrier devices, they are trying to use polymer solutions [Falabella C.A. Cross-linked hyaluronic acid films to reduce intra-abdominal postsurgical adhesions in an experimental model / CA Falabella, W. Chen / / Dig. Surg.-. 2009.- Vol. 26, N 6.- P. 476-481], solid membranes [Hyaluronan derivatives in postsurgical adhesion prevention / D. Pressato, E. Bigon, M. Dona et al. / / in: Hyaluronan: Proceedings of an International Meeting, September 2000, North East Wales Institute, UK, Woodhead.- Publishing, Cambridge, England, 2002. - P. 491-499], preformed [A novel hyaluronan-based gel in laparoscopic adhesion prevention: preclinical evaluation in an animal model / PAD Laco, M. Stefanetti, D. Pressato et al. / / Fertil. Steril.- 1998.- Vol. 69.- P. 318-323] or in situ produced hydrogels [Next-generation hydrogel films as tissue sealants and adhesion barriers / SL Bennett, DA Melanson, DF Torchiana et al. / / J. Card. Surg.- 2003.- Vol. 18.- P. 494-499]. The use of crystalloid solutions for long-term separation of the peritoneal layers is inappropriate, since the absorption of water and electrolytes from the abdominal cavity occurs quickly—in humans, up to 500 ml of isoosmolar sodium chloride solution is absorbed in less than 24 hours [Kinetics of peritoneal fluid absorption in adult man / L. Shear, C. Swartz, J. Shinaberger et al. / / N. Engl. J. Med.- 1965.- Vol. 272.- P. 123-127]. Since remesothelialization of the peritoneal surfaces requires 5-8 days, the crystalloid solution will be absorbed long before the process of fibrin deposition and adhesion formation is complete. According to research data, the frequency of re-adhesion formation in patients who received crystalloid solutions is 80% [De Cherney A.N. Clinical problem of intraperitoneal postsurgical adhesion formation following general surgery and the use of adhesion prevention barriers / AH De Cherney, GS di Zerega / / Surg. Clin. North. Am.- 1997.- Vol. 77.- P. 671-688].

[0018] Attempts are being made to use polymeric materials, in particular glucose polymers (Dextran 70, isodextrin), carboxymethylcellulose, and hyaluronic acid preparations.

[0019] Dextran 70 (32% dextran 70 (Hyskon, Pharmacia, Sweden)) has previously been widely used to prevent adhesions. The main properties of the drug are that the dextran solution is slowly absorbed and attracts fluid into the abdominal cavity, inhibiting the formation of blood clots [Gutmann JN Principles of laparoscopic microsurgery and adhesion prevention / JN Gutmann, MP Diamond / / in: Practical Manual of Operative Laparoscopy and Hysteroscopy: Ed. Azziz R., Murphy AA- New York: Springer, 1992.- P. 55-64]. However, long-term observations have failed to reveal a reduction in adhesion formation. Moreover, significant side effects were noted, such as ascites, weight gain, pleural effusion, lip swelling, liver dysfunction, and, although rare, disseminated intravascular coagulation and anaphylaxis [di Zerega GS Contemporary adhesion prevention / GS di Zerega / / Fertil. Steril. - 1994.- Vol. 61.- P. 219-235]. The results were unsatisfactory [Tulandi T. Intraperitoneal instillates / T. Tulandi / / Infertil. Reprod. Med. Clin. North. Am.- 1994.- Vol. 5.- P. 479-483], and the drug is currently practically not used.

[0020] The use of local barriers in the form of porous polytetrafluoroethylene mesh is difficult due to the formation of a pseudocapsule [The Surgical Membrane Study Group: Prophylaxis of pelvic sidewall adhesions with Gore-Tex surgical membrane: A multicenter clinical investigation / / Fertil. Steril.- 1992.- Vol. 57.- P. 921-923]. In addition, this film is technically difficult to use in laparoscopic surgery [Tulandi T. Adhesion prevention in laparoscopic surgery / T. Tulandi / / Int. J. Fertil. Menopausal. Stud.- 1996.- Vol. 41.- P. 452-457]. It must be physically fixed in place, and it is not absorbable. Therefore, it must either be left in place permanently or later surgically removed. The act of removal itself implies some surgical trauma and leads to the formation of adhesions. Technical difficulties and inconveniences during use made the drug unpopular, and the remedy is now practically not used.

[0021] Oxidized reduced cellulose (Interceed) is the only adjuvant approved for the specific purpose of preventing postsurgical adhesions. The drug reduces adhesion formation compared to that after carefully and meticulously performed surgery, reducing both the damaged surface area and the incidence of adhesion formation with a 20% advantage [Interceed (TC7) Adhesions Barrier Study Group: Prevention of postsurgical adhesions by Interceed (TC7), an absorbable adhesion barrier: A prospective, randomized multicenter clinical study / / Fertil. Steril. - 1989. - Vol. 51. - P. 933-938]. When applied to the damaged peritoneum, the drug turns into a gel within 8 hours [Synergistic effects of Interceed (TC7) and heparin in reducing adhesion formation in the rabbit uterine horn model / MP Diamond, CB Linsky, T. Cunningham et al. / / Fertil. Steril.- 1991.- Vol. 55.- P. 389-394], it is easily applied during laparoscopy and does not require suturing. However, even slight bleeding during application of the preparation leads to blood soaking and warping of the material. Fibroblasts grow along the strands of clotted blood with subsequent collagen deposition and vascular proliferation [Frankfurter D. Pelvic adhesive disease / D. Frankfurter, AH De Cherney / / Postgrade Obstet. Gynecol.- 1996.- Vol. 16.- P. 1-5]. This means that the presence of blood in the abdominal cavity eliminates any positive effect of the drug [Effect of blood on the efficacy of barrier adhesion reduction in the rabbit uterine horn model / CB Linsky, MP Diamond., GS di Zerega et alJ / Infertility.- 1988.- Vol. 11.- P. 273-280].

[0022] Summarizing the currently established approaches to the prevention of adhesion formation after surgical interventions on the abdominal cavity, V.A. Burlev et al. (2009) [Burlev V.A. Peritoneal adhesions: from pathogenesis to prevention V.A. Burlev, E.D. Dubinskaya, A.S. Gasparov / / Problems of reproduction. - 2009. - N ° 3. - P. 36-44] regretfully state that none of the existing methods of preventing the adhesion process is sufficiently effective (moreover, they are quite expensive), which requires further research to improve the effectiveness of anti-adhesion measures.

[0023] The closest in technical essence to the proposed method is a method for preventing adhesion formation by introducing a mixture of sterile Lintex-Mesogel gel and Derinat into the serous cavity [Method for preventing the formation of postoperative adhesions: patent 2363476 Russian Federation: MKP51: A61K31 / 711, A61K31 / 717, A61P41 / 00 / Gomon M.S., Lipatov V.A., Konoplya A.I., Bezhin A.I., Loktionov A.L., Kasyanova M.A., Sukovatykh B.S., Godova A.Yu.; applicant and patent holder Gomon M.S., Lipatov BA- JY2 2007147670 / 14; declared 20.12.2007; published 10.08.09, Bull. JYO 22.- 6 p.].

[0024] The known method is carried out as follows. During abdominal surgery, for example, laparotomic or laparoscopic surgery, and / or before closure of the serous cavity at the final stage of the intervention, those areas where there is a high probability of primary or recurrent adhesion development (e.g., deserotic areas, areas of imposed anastomoses, areas of obvious or probable inflammation, areas of injury after dissection of adhesions, areas of drying of the peritoneum, etc.) are treated with the sterile Lintex-Mesogel gel and Derinat deposited in it. The volume of Derinat ranges from 1% to 25% of the total volume of the mixture. The combination of Derinat solution and polymer gel is achieved by extemporaneous mixing, immediately before use, in the required proportions until homogeneous, while the ratio of the volumes of gel and Derinat solution (based on the calculation of 1.The dosage of Derinat (5 mg / kg) should be such that the solution introduced into the system constitutes no more than 25% of the total volume, as a larger amount of liquid will reduce the gel's viscosity and, consequently, its anti-adhesion properties. For prophylactic purposes, the gel is applied to the serous surface using a syringe or squeezed from the container used for mixing onto the surgeon's hand. It is then applied with lubricating movements to the deperitonealized, deserous surface and areas where adhesions may form (the presence of signs of inflammation or ischemia: edema, hyperemia, vasodilation, discoloration, impaired peristalsis, decreased pulsation of the abdominal vessels, etc.). In diffuse processes (for example, after abdominal cavity sanitation in patients with widespread peritonitis), Derinat gel is administered at a dose calculated according to the table by G. DiZerega (1999): for humans - 2.4 ml / kg, for animals (rats) - 10.7 ml / kg. When performing operations under conditions. For laparoscopic approaches, manipulator-injectors are used to introduce the gel with Derinat deposited in it.

[0025] A disadvantage of this method is the need to prepare the preparation under sterile conditions directly at the time of surgery, which complicates the procedure. Other disadvantages include the difficulty of achieving homogeneity with this preparation method, the difficulty of dosing Derinat (requiring weighing), the need for special manipulators during laparoscopic gel application, and the absence of components that inhibit the activity of fibroblasts—the cells whose synthetic activity causes adhesion formation.

[0026] It is known that the p38 MAP kinase blocker SB203580 is an inhibitor of the production of proinflammatory cytokines [Badger AM, Bradbeer JN, Votta B. et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein / p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function / / J. Pharmacol. Exp. Ther.- 1996.- Vol. 279.- P. 1453-1461].

[0027] However, the authors of this invention are not aware of, and no information has been found in the available literature on the use of p38 MAP kinase blockers as a means of anti-adhesive activity.

[0028] DETAILED DESCRIPTION OF THE INVENTION

[0029] The objective of the claimed invention is to obtain compounds intended for the treatment and prevention of adhesion formation, as well as to obtain pharmaceutical compositions based on them, including an effective amount of one and / or several of the above compounds and a pharmaceutically acceptable carrier, diluent or excipient. Another objective of the invention is to develop a method for preventing adhesions that allows for the avoidance of additional drug administration in the postoperative period.

[0030] The authors of the present invention have unexpectedly discovered that p38 MAP kinase blockers can be used for the treatment and prevention of adhesion formation. In particular, the substance [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole], also known as 8B203580 (the chemical structural formula is shown in A. Cuenda et al, FEBS Letters 364(1995) 229-233), as well as other new compounds of type (I)-(VII) (described below), obtained according to the present invention in concentrations from 0.1 to 100 μg / ml (based on the active substance that blocks p38 MAP kinase activity) and in a volume from 0.1 to 500 ml (depending on the volume of the serous cavity), sufficient for a single wetting of the entire surface of the serous membrane with this solution, ensure the absence of the adhesion process in the area of ​​damage to the serous membrane (Fig. 1).

[0031] According to the invention, it is characterized by the production of new compounds for the prevention or treatment of adhesive disease, which have the ability to specifically suppress the excessive proliferative response when serous membranes are involved in the pathological process, as well as the creation of a pharmaceutical composition containing one and / or several of these compounds for the treatment and / or prevention of adhesive disease, and a method for the prevention or treatment of adhesion formation based on the use of these compounds.

[0032] The claimed group of the above compounds can be characterized by the following structural formulas

[0033] LAWYER'S CLAIM RULE 91 ISA / RU type (I):

[0035] or (IV):

[0037] or (VII):

[0038] Where Ri is the structural unit of water-soluble basic polymers of natural or synthetic origin; x and y are integers. The values ​​of X and Y depend on the number of monomer units in the polymer molecule. Essentially, each polymer molecule has n monomers. Some of these monomers bind the p38 blocker in solution, while others remain unbound. In this case, (X + Y) = n (or, in some cases, X + Y + Z = n), where n can be any integer.

[0039] The invention also relates to the use of the substance SB203580 for a new purpose, namely as an agent with anti-adhesive activity.

[0040] In addition, the claimed invention relates to pharmaceutical compositions that are characterized by the presence of an effective amount of one of the above-described compounds of type (I)-(VII), or combinations thereof with each other, or the compound SB203580, or combinations of the compound SB203580 and one or more of the compounds of type (I)-(VII), as well as a pharmaceutically acceptable carrier, diluent or excipient.

[0041] The amount of active ingredient in the pharmaceutical composition, i.e., the compound of type (I) to (VII), or the compound SB203580, or combinations thereof, required to obtain a therapeutic effect will, of course, vary depending on both the specific compound and the route of administration, and on the size of the serous membrane of the patient to be treated. A suitable dose of the compound of type (I)-(VII), or the compound SB203580, or combinations thereof for treating the serous cavity is from 0.01 μg to 50 mg, calculated as the substance blocking p38 MAP kinase activity.

[0042] Although the active ingredient can be administered separately as the crude chemical, it is preferably included in a pharmaceutical composition. Preferably, the active ingredient comprises between 0.00001% and 99.99999% of the composition.

[0043] Accordingly, the finished composition may be presented as standard dosage units or single doses and may be prepared using any known pharmaceutical methods. One option for preparing the pharmaceutical composition may be the methods described in A.I. Tikhonov and T.G. Yarnykh's "Technology of Medicines," NFAU Publishing House, 2002, pp. 228, 229, and 242. All methods include contacting the active ingredient with a carrier, which comprises one or more auxiliary ingredients. Generally, the compositions are prepared by uniformly and thoroughly bringing the active ingredient into contact with the liquid carrier.

[0044] The above-described pharmaceutical composition according to the present invention can be made and administered in the form of a perfusion liquid, a spray, a solution for spraying or vaporization, a foamy aerosol preparation, a gel or suspension, as well as in the form of other acceptable liquid dosage forms.

[0045] Regarding the method of administration, it is more acceptable if the solution is applied directly to the surface of the serous membrane, including incision sites and organs, or after preparing the solution for the prevention of adhesion in the form of a spray, it is sprayed with a spray device. After preparing the solution for preventing adhesion formation in the form of a spray, it can be sprayed onto the required areas, while the solution, which acts as a means for preventing adhesion formation in the incision area, can be sprayed widely and evenly onto the required areas, and the required area where it is necessary to prevent adhesion formation can be covered with a sufficient layer of the solution.

[0046] As a sprayer, you can use either a spray with two pneumatic atomizers, in which droplets of solution are carried by air or carbon dioxide, or a spray with one pneumatic atomizer, in which the solution is converted into small particles under pressure.

[0047] The advantageous effect of the present invention is achieved by the fact that compounds of type (I)-(VII) are obtained by conjugation of the base polymer and a protonated derivative of pyridineimidazole or pyridinepyrrole, and also by the fact that a pharmaceutical composition is prepared that includes an effective amount of a compound of type (I)-(VII) and / or SB203580, as well as combinations thereof and a pharmaceutically acceptable carrier, diluent or excipient.

[0048] For the preparation of compounds of type (I)-(VII), any suitable base polymers can be used. Preferably, polyethyleneimine and its copolymers, polyvinylpyridines and their copolymers, polyvinylimidazole and its copolymers, polyvinyltriazoles and their copolymers, polyvinyltetrazole and its copolymers, chitosan and its derivatives, salts of carboxymethylcellulose, salts of polyacrylic acid and its copolymers, salts of polymethacrylic acid and its copolymers, salts of polymethylmethacrylic acid and its copolymers can be used as the base polymer. The advantageous effect of this invention is also achieved by the fact that for the prevention or treatment of a disease or condition in which there is a possibility of the formation or growth of adhesions, the intracavitary administration of this pharmaceutical composition is carried out during a surgical, minimally invasive or diagnostic intervention.

[0049] The essence of the claimed method is that immediately after completion of the surgical and / or diagnostic intervention, any suitable p38 MAP kinase blocker is introduced into the serous cavity.

[0050] In one embodiment of the claimed method, p38 MAP kinase blockers, in particular the proposed substance SB203580, or one of the compounds of types (I)-(VII), or combinations thereof, are administered as a sterile aqueous solution at a concentration of 0.1 to 100 μg / ml (based on the active substance that blocks p38 MAP kinase activity) and in a volume sufficient to wet the entire surface of the serous membrane with said solution. Administration is carried out once at a dose sufficient to block at least half of the p38 MAP kinase activity in the damaged area of ​​the serous membrane.

[0051] A distinctive feature of the claimed method is that the administration of a pharmaceutical composition containing the substance SB203580, or one or more of the compounds of type (I)-(VII), or a combination thereof, is carried out to a subject in need thereof, whose condition or disease is a disease or condition of the serous membranes.

[0052] The claimed method can be used for diseases or conditions accompanied by the appearance of exudate in the serous cavity, the appearance of blood in the serous cavity, as well as those accompanied by damage to the serous membrane. The compounds intended for the prevention of adhesion formation, pharmaceutical compositions based on them, and a method for the prevention and treatment of adhesive disease, which constitute the claimed invention, are intended for use in experimental and / or clinical medicine and / or veterinary science. The feasibility of this application is supported by the methods and means described in the application.

[0053] Thus, the authors of the invention have established and proven that p38 MAP kinase blockers can be used as agents with anti-adhesive activity.

[0054] Furthermore, the authors succeeded in solving the stated objectives of the invention, namely, obtaining compounds effective for the treatment and / or prevention of adhesion formation, as well as producing pharmaceutical compositions based on them, comprising an effective amount of one of the above-mentioned compounds and / or a combination thereof and a pharmaceutically acceptable carrier, diluent, or excipient. Furthermore, the authors succeeded in developing an effective method for preventing adhesions, eliminating the need for additional drug administration in the postoperative period.

[0055] BRIEF DESCRIPTION OF DRAWINGS

[0056] Figure 1 (therapeutic efficacy of the p38 MAP kinase blocker SB203580)

[0057] Figure 1 shows a histological section of the intestinal wall in the area of ​​adhesion, showing the absence of an adhesion process in the animal of the experimental group even in the area of ​​damage to the peritoneum and the application of a postoperative suture (position C), stained using the Van Gieson method.

[0058] Figure 2 (therapeutic efficacy of the p38 MAP kinase blocker compound SB203580) Figure 2 shows a histological section of the intestinal wall at the site of an adhesion in an animal from the control group (van Gieson stain). The adhesions formed are characterized by extensive length, dense connective tissue (position A), and the presence of vascularization (position B).

[0059] Figure 3 (therapeutic efficacy of the p38 MAP kinase blocker—type (I) compounds, where R1 represents the structural units of polyvinylimidazole)

[0060] Figure 3 shows a histological section of the intestinal wall at the adhesion site (position A) in a control animal, 30 days after modeling abdominal adhesions, stained using the Van Gieson method. The adhesion is of the "gut-to-gut" type (position A), and is well vascularized (position B).

[0061] Figure 4 (therapeutic efficacy of the p38 MAP kinase blocker—type (I) compounds, where R1 represents the structural units of polyvinylimidazole)

[0062] Figure 4 shows a histological section of the intestinal wall in the adhesion area. It demonstrates the absence of adhesions in the experimental animal, even in the area of ​​peritoneal injury and postoperative suture placement (Position C). 30 days after the adhesion modeling in the abdominal cavity, stained using the Van Gieson method.

[0063] Figure 5 (therapeutic efficacy of the p38 MAP kinase blocker—type (I) compounds, where R1 represents the structural units of polyvinylimidazole)

[0064] Figure 5 shows the severity of the adhesion process on days 7, 14 and 30 in animals of the control group compared to animals of the experimental group. Drawing 6

[0065] UV-VIS spectrum of an aqueous solution of a protonated salt of compound type (I), where R1 represents the structural units of polyvinylimidazole. Line No1 is water, line 3U22 is an aqueous solution of polyvinylimidazole, line JN°3 is compound (I), line 3U24 is compound (1) + polymer polyvinylimidazole.

[0066] Drawing 7

[0067] UV-VIS spectrum of an aqueous solution of a protonated salt of compound type (I), where R1 represents structural units of carboxymethyl cellulose. Line No1 is water, line 3U22 is an aqueous solution of polyvinylimidazole, line JN°3 is compound (I), line 3U24 is compound (1) + carboxymethyl cellulose polymer.

[0068] Drawing 8

[0069] UV-VIS spectrum of an aqueous solution of a protonated salt of compound type (I), where R1 represents the structural units of polyvinyltriazole. Line No1 is water, line ^2 is an aqueous solution of polyvinylimidazole, line N23 is compound (I), line ^4 is compound (1) + polymer polyvinyltriazole.

[0070] DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS OF THE INVENTION

[0071] The following examples serve to illustrate but do not limit the invention.

[0072] Example 1

[0073] Obtaining compounds of type (1)-(UP) possessing anti-adhesive activity. Compounds of type (I)-(VII) are obtained in three stages in accordance with the following basic schemes for obtaining 1-3.

[0074] To synthesize substances of type (I)-(VII) with anti-adhesive activity, in the first stage an aqueous solution of a polymer with pronounced basic properties is prepared, for example, polyvinylimidazole according to scheme 1.

[0075] Then, in the second stage, aqueous solutions of protonated salts of compounds of type (1)-(UP) are prepared by dissolving them in an aqueous solution of any inorganic or organic acid (NAp) in accordance with scheme 2. UV-VIS spectra of the resulting aqueous solutions of protonated salts of compounds of type (I)-(VII) are recorded.

[0076] In the third stage, the obtained aqueous solution of the polymer and an aqueous solution of the protonated salt of compounds of type (I)-(VII) are mixed, and kept for 1 hour at room temperature for the complete reverse destruction of the protonated salt of the compound (removal of the acid under the action of a highly basic environment of aqueous solutions of polymers), thus forming compounds of type (I)-(VII), which are a conjugate of the main polymer and the active substance (Scheme 3).

[0077] UV-VIS spectra are recorded again, and based on their transformation (in comparison with the protonated salt), the formation of compounds of type (I)-(VII) with polymers is confirmed.

[0078] The compounds of type (I)-(VII) obtained in this way, in contrast to the initial compounds without polymer, can be used for the treatment or prevention of adhesion formation

[0079] Scheme 1.

[0080] Obtaining an aqueous polymer solution Θ

[0081] Polymer + n H20 Polymer(H) n (OH) n

[0082] An example of obtaining an aqueous solution of polyvinylimidazole

[0084] An example of obtaining an aqueous solution of salts of arbo-methylcellulose

[0086] R=H,CH2C(0)OM; M=Na + , K + , NH4 + etc.

[0087] An example of obtaining an aqueous solution of chitosan

[0089] Scheme 2.

[0090] Preparation of a water-soluble protonated salt of a compound of type (I)-(VII)

[0092] Scheme 3

[0093] Obtaining compounds of type (I)-(VII)

[0094] Example 2

[0095] In accordance with schemes 1-3, which were given in the above example 1, a substance of type (I) was obtained based on the natural polymer chitosan:

[0096] , where x and y are integers.

[0097] Example 3

[0098] In accordance with schemes 1-3, which were given in the above example 1, a substance of type (I) was obtained on the basis of the synthetic polymer polyvinylimidazole:

[0100] , where x and y are integers Example 4.

[0101] In accordance with schemes 1-3, which were given in the above example 1, a substance of type (I) was obtained on the basis of the synthetic polymer carboxymethyl cellulose:

[0103] , where x and y are integers. Example 5.

[0104] Laboratory animals (9-month-old Wistar rats weighing 220-250 g) were used to simulate abdominal adhesions by damaging the cecum wall and scarifying the abdominal wall in the projection of the damaged area. The studies were carried out in compliance with the principles set forth in the Convention for the Protection of Vertebrate Animals used for Experimental and Other Purposes (Strasbourg, France, 1986), as well as in accordance with the rules for the humane treatment of animals, which are regulated by the "Rules for Conducting Work Using Experimental Animals" (Appendix to the Order of the USSR Ministry of Health dated 12.08.1977, No. 755).

[0105] The study used 10 animals, which were divided into 2 groups: experimental and control.

[0106] Before abdominal wall suturing, a sterile solution of the p38 MAP kinase inhibitor SB203580 was injected into the abdominal cavity of animals in the experimental group in a single dose of 3 ml at a concentration of 10 μg / ml. The calculation is based on the minimum volume of fluid required to wet the entire peritoneal surface (diZerega GS Peritoneum, peritoneal healing and adhesion formation / GS diZerega / / in: Peritoneal surgery: Ed. GS diZerega. - Berlin-Heidelberg-New York: Springer, 2006. - P. 3-38), and the concentration is based on achieving IC50 in the border layer of cells.

[0107] The control group of animals was administered the appropriate amount of saline solution.

[0108] On the 28th day after the peritoneal injury, all animals were subjected to necropsy for a thorough examination of the abdominal organs with an assessment of the severity and prevalence of the adhesion process, deformation of the abdominal organs and the distribution structure of individual types of adhesions. The severity of the adhesion process was assessed using a point assessment according to the micro- and macroscopic adhesion assessment scales [Micronized purified flavonoid fraction may prevent the formation of intraperitoneal adhesions in rats / / HG Yilmaz, IH Tacyildiz, C. Keles et al. / / Fertil. Steril.- 2005.- Vol. 84, Suppl. 2.- P 1083-1087].

[0109] The visceral peritoneum and abdominal organs involved in the adhesion process were subjected to histological examination after fixation in FineFIX solution (Milestone), embedding in paraffin, and staining of sections with hematoxylin and eosin and according to Van Gieson.

[0110] It was found that in animals in the control group, abdominal adhesions were registered in 100% of cases, with intestinal wall-to-intestinal wall adhesions being registered in 100% of cases. Figure 2 shows a histological section of the intestinal wall in the adhesion area (position A) in an animal from the control group (van Gieson staining). The formed adhesions are characterized by extensive length, dense connective tissue (position A), and the presence of vascularization (position B).

[0111] Intestinal wall-to-intestinal wall adhesions were not observed in any of the experimental animals. Figure 1 (appendix to the application description) shows the absence of adhesions. in the animal of the experimental group, even in the area of ​​damage to the peritoneum and the application of the postoperative suture (position C), stained according to Van Gieson.

[0112] In the control group of animals it was 7 points, in the experimental group it was 2 points (p<0.01).

[0113] As a result of the conducted study, the obtained data allow us to consider that the proposed method allows for the prevention of adhesion formation in the serous cavity after surgical interventions.

[0114] Thus, the claimed method allows for the prevention of adhesions in the serous cavity with a single administration of the drug directly at the stage of completion of the surgical intervention without additional trauma, which simplifies the method of preventing adhesion formation, reduces the risk of organ trauma and the risk of infection of the serous cavity.

[0115] Example 6.

[0116] Laboratory animals (9-month-old Wistar rats weighing 220-250 g) were used to simulate abdominal adhesions by damaging the cecum wall and scarifying the abdominal wall in the projection of the damaged area. The studies were carried out in compliance with the principles set forth in the Convention for the Protection of Vertebrate Animals used for Experimental and Other Purposes (Strasbourg, France, 1986), as well as in accordance with the rules for the humane treatment of animals, which are regulated by the "Rules for Conducting Work Using Experimental Animals" (Appendix to the Order of the USSR Ministry of Health dated 12.08.1977, No. 755).

[0117] The study used 30 animals, which were divided into 2 groups: experimental and control. Before suturing the abdominal wall of the animals in the experimental group, a pharmaceutical composition containing the compound according to Example 2 was introduced into the abdominal cavity at a concentration of 2 x 10 ~3mol / l, in a volume of 3 ml (the calculation is based on the minimum volume of fluid required to cover the peritoneal surface [diZerega GS Peritoneum, peritoneal healing and adhesion formation / GS diZerega / / in: Perotoneal surgery: Ed. GS diZerega.- Berlin-Heidelberg-New York: Springer, 2006.- P. 3-38]) once. The control group of animals was administered the corresponding amount of saline.

[0118] On days 7, 14, and 28 after peritoneal injury, the animals underwent necropsy. A thorough examination of the abdominal organs was performed, assessing the severity and extent of adhesions, the deformation of the abdominal organs, and the distribution of individual types of adhesions. The visceral peritoneum and abdominal organs involved in the adhesion process were subjected to histological examination after fixation in FineFIX (Milestone), paraffin embedding, and sections stained with hematoxylin and eosin and van Gieson staining.

[0119] It was found that in animals of the control group, the adhesion process in the abdominal cavity was registered in 100% of cases, with the intestinal wall-to-intestinal wall adhesions being registered in 100% of cases. The formed adhesions were characterized by a large length, connective tissue density, and the presence of vascularization (appendices to the description of the application, Fig. 3). Thus, Fig. 3 shows a histological section of the intestinal wall in the adhesion area (position A) in an animal of the control group, 30 days after the modeling of the adhesion process in the abdominal cavity, stained using the van Gieson method. An adhesion of the "intestine-to-intestine" type (position A), well vascularized (position B) is shown. Intestinal wall-to-intestinal wall adhesions were not observed in any animal in the experimental group. Figure 4 shows the absence of adhesions in an animal in the experimental group, even in the area of ​​peritoneal injury and postoperative suture placement (Position C), 30 days after the simulated adhesion process in the abdominal cavity, stained using the Van Gieson method.

[0120] The severity of the adhesion process in animals of the control group was significantly higher than in the experimental group on days 7, 14 and 30 (Figure 5).

[0121] Example 7.

[0122] In sequential experiments on 8 experimental groups of male Wistar rats (25 rats in each experimental group) weighing 180-200 g at the age of 9 months, the effect of type (I)-(VII) preparations based on natural polymers chitosan, carboxymethylcellulose, polyvinyl tetrazole, polyethyleneimine, polyvinyltriazole, and polyacrylic acid on the prevention and course of adhesive disease in an experimental model of adhesions in the abdominal cavity was studied. The studies were performed in accordance with the methods described in Examples 5 and 6 of this invention.

[0123] Preparations of type (I)-(VII) based on natural polymers of chitosan, carboxymethylcellulose, polyvinyltetrazole, polyethyleneimine, polyvinyltriazole, polyacrylic acid (at a dose of 10 mg / kg kg in terms of a substance blocking p38 MAP kinase activity) were administered to each experimental group (once, at the end of the operation) in the form of a solution after modeling adhesive disease.

[0124] The control group consisted of animals that received a similar volume of saline intraperitoneally. On days 7, 14, and 28 after peritoneal injury, the animals underwent necropsy. A thorough examination of the abdominal organs was performed, assessing the severity and extent of adhesions, the deformation of the abdominal organs, and the distribution of individual types of adhesions. The visceral peritoneum and abdominal organs involved in the adhesion process were subjected to histological examination after fixation in FineFIX (Milestone), paraffin embedding, and sections stained with hematoxylin and eosin and van Gieson staining.

[0125] It was found that in animals of the control group, the adhesion process in the abdominal cavity was registered in 100% of cases, and adhesions of the intestinal wall-to-intestinal wall type were registered in 100% of cases.

[0126] In animals of each of the 6 experimental groups, intestinal wall-to-intestinal wall adhesions were not recorded in any case.

[0127] The severity of the adhesion process in animals of the control group was significantly higher than in the experimental group on days 7, 14 and 30.

Claims

Invention formula 1. Joint type (I): ###0001### CORRECTED SHEET (RULE 91) ISA / RU or (IV): ###0002### ###0003### ###0004### or (VII): CORRECTED SHEET (RULE 91) ISA / RU ###0005### where R] is a structural unit of water-soluble polymers of basic nature of natural or synthetic origin; x and y are integers.

2. The compound according to claim 1, wherein R1 represents structural units of chitosan and its derivatives.

3. The compound according to claim 1, wherein R1 represents structural units of polyvinyltetrazole and its copolymers.

4. The compound according to claim 1, wherein R1 represents structural units of carboxymethylcellulose salts.

5. The compound according to claim 1, wherein R1 represents structural units of polyvinylimidazole and its copolymers.

6. The compound according to claim 1, wherein R1 represents structural units of polyethyleneimine and its copolymers.

7. The compound according to claim 1, wherein R1 represents structural units of polyvinylpyridines and their copolymers.

8. The compound according to claim 1, wherein R1 represents structural units of polyvinyltriazoles and their copolymers.

9. The compound according to claim 1, wherein R1 represents structural units of salts of polyacrylic acid and its copolymers.

10. The compound according to claim 1, wherein R1 represents structural units CORRECTED SHEET (RULE 91) ISA / RU salts of polymethacrylic acid and its copolymers.

11. A pharmaceutical composition comprising an effective amount of one of the compounds according to claim 1 or a combination thereof and a pharmaceutically acceptable carrier, diluent or excipient.

12. A pharmaceutical composition comprising an effective amount of the compound: 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole, a pharmaceutically acceptable carrier, diluent or excipient.

13. A pharmaceutical composition comprising an effective amount of the compound: 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-III-imidazole and one or more compounds according to claim 1, a pharmaceutically acceptable carrier, diluent or excipient.

14. The use of p38 MAP kinase blockers as a means of anti-adhesive activity.

15. The use according to claim 14, wherein the p38 MAP kinase blocker is the compound 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1 H-imidazole.

16. The use according to claim 14, wherein the p38 MAP kinase blocker is any of the compounds according to claim 1 or a combination thereof with each other or with the compound 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole.

17. A method for the prevention and / or treatment of a disease or condition in which there is a possibility of the formation and / or growth of adhesions, comprising the intracavitary administration of a drug, characterized in that an effective amount of a p38 MAP kinase blocker is administered.

18. The method according to claim 17, characterized in that 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole is used as the p38 MAP kinase blocker.

19. The method according to claim 17, characterized in that as a p38 MAP blocker CORRECTED SHEET (RULE 91) ISA / RU kinases use an effective amount of any of the compounds according to claim 1 or their combination with each other or with the compound 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole.

20. The method according to paragraph 17, used when performing any operations and manipulations with invasion into the serous cavity, including minimally invasive ones, including laparoscopy, thoracoscopy, arthroscopy, but not limited to them.

21. The method according to paragraph 17, used in diseases or conditions accompanied by the appearance of exudate in the serous cavity.

22. The method according to paragraph 17, used in diseases or conditions accompanied by the appearance of blood in the serous cavity.

23. The method according to paragraph 17, used in diseases or conditions accompanied by damage to the serous membrane.

24. The method according to claim 17, in which the compound is introduced into the serous cavity once, immediately after completion of the surgical and / or diagnostic intervention, in the form of a sterile solution, in a volume sufficient to wet the entire surface of the serous cavity. CORRECTED SHEET (RULE 91) ISA / RU